Tuberculosis cost-effectiveness of therapy: Difference between revisions
No edit summary |
m (Changes made per Mahshid's request) |
||
| Line 40: | Line 40: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Primary care]] | [[Category:Primary care]] | ||
Revision as of 19:02, 18 September 2017
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberculosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Tuberculosis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Tuberculosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Treatment of tuberculosis must be analysed for relative cost effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is highly prevalent. Unless there is severe complications it is highly recommended to treat the TB patient in ambulatory care rather than inpatient services.[1]
Cost effectiveness of therapy
While measurements of morbidity and mortality are key considerations for estimating the burden of disease in populations, they provide an incomplete picture of the adverse impact of ill health on human welfare. In particular, the economic consequences of poor health can be substantial.
Analysis of the economic impact of ill-health addresses a number of policy questions concerning the consequences of disease or injury. Some of these questions relate to the microeconomic level of households, firms or government – such as the impact of ill-health on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the aggregate impact of a disease on a country’s current and future gross domestic product (GDP).
WHO proposes a defined conceptual framework within which the economic impact of diseases and injuries can be considered and appropriately estimated. [2]
The current regimen costs about US$ 4000 per patient, exclusive of laboratory, human resource and patient opportunity costs. [3]
The cost effectiveness in various tubercular control interventions in Africa region is give below. [3]
| Intervention | Yearly costs with 95% coverage level |
|---|---|
| Minimal DOTS | 366.3 million $ |
| Full DOTS | 612.2 million $ |
| Minimal DOTS with resistant cases | 495.9 million $ |
| Full combination | 739.4 million $ |
References
- ↑ Fitzpatrick C, Floyd K (2012). "A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis". Pharmacoeconomics. 30 (1): 63–80. doi:10.2165/11595340-000000000-00000. PMID 22070215.
- ↑ "Cost effectiveness and strategic planning".
- ↑ 3.0 3.1 "Cost effectiveness purposed by WHO".